生物力学鞋对膝骨关节炎患者膝痛的影响:BIOTOK随机临床试验
该随机临床试验在瑞士大学医院纳入220例有症状且影像学确诊的膝骨关节炎患者,比较个体化校准生物力学鞋与对照鞋对24周随访时膝痛的影响。结果显示生物力学鞋组WOMAC疼痛评分改善优于对照鞋组,组间差异有统计学意义但临床重要性不确定。
要点
- 生物力学鞋组24周WOMAC疼痛评分从4.3降至1.3,对照鞋组从4.0降至2.6。
- 24周时组间疼痛评分差异为-1.3(95%CI -1.8至-0.9),P<.001。
- 物理功能、僵硬和全局评分结果与疼痛一致,严重不良事件两组均与治疗无关。
核心结论
- 在有症状的膝骨关节炎患者中,与对照鞋相比,生物力学鞋在24周随访时使疼痛改善有统计学意义,但临床重要性不确定。
研究设计与样本
- 随机临床试验,在瑞士一家大学医院开展,纳入220例有症状且影像学确诊的膝骨关节炎患者。
- 参与者随机分为生物力学鞋组(n=111)和对照鞋组(n=109),随访24周。
- 主要结局为24周时WOMAC疼痛子评分(标准化0至10分)。
主要发现
- 24周时生物力学鞋组WOMAC疼痛评分从4.3降至1.3,对照鞋组从4.0降至2.6,组间差异-1.3(95%CI -1.8至-0.9),P<.001。
- 24周时WOMAC物理功能子评分组间差异-1.1(95%CI -1.5至-0.7)。
- 24周时WOMAC僵硬子评分组间差异-1.4(95%CI -1.9至-0.9),全局评分组间差异-1.2(95%CI -1.6至-0.8)。
- 生物力学鞋组发生3例严重不良事件,对照鞋组9例(2.7% vs 8.3%),均与治疗无关。
关键数值与推荐
- 主要结局采用WOMAC疼痛子评分,标准化范围为0(无症状)至10(极度症状)。
- 24周时WOMAC疼痛评分组间差异-1.3(95%CI -1.8至-0.9),P<.001。
临床怎么用
- 生物力学鞋可能改善膝骨关节炎患者的疼痛和功能,但临床价值需进一步研究确认。
- 在推荐该设备前,需评估长期疗效和安全性,并等待重复验证。
局限性
- 随访仅24周,长期疗效和安全性未知。
- 疼痛改善的临床重要性不确定。
- 结果需进一步重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Individually calibrated biomechanical footwear therapy may improve pain and physical function in people with symptomatic knee osteoarthritis, but the benefits of this therapy are unclear. OBJECTIVE: To assess the effect of a biomechanical footwear therapy vs control footwear over 24 weeks of follow-up. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at a Swiss university hospital. Participants (N = 220) with symptomatic, radiologically confirmed knee osteoarthritis were recruited between April 20, 2015, and January 10, 2017. The last participant visit occurred on August 15, 2017. INTERVENTIONS: Participants were randomized to biomechanical footwear involving shoes with individually adjustable external convex pods attached to the outsole (n = 111) or to control footwear (n = 109) that had visible outsole pods that were not adjustable and did not create a convex walking surface. MAIN OUTCOMES AND MEASURES: The primary outcome was knee pain at 24 weeks of follow-up assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore standardized to range from 0 (no symptoms) to 10 (extreme symptoms). The secondary outcomes included WOMAC physical function and stiffness subscores and the WOMAC global score, all ranging from 0 (no symptoms) to 10 (extreme symptoms) at 24 weeks of follow-up, and serious adverse events. RESULTS: Among the 220 randomized participants (mean age, 65.2 years [SD, 9.3 years]; 104 women [47.3%]), 219 received the allocated treatment and 213 (96.8%) completed follow-up. At 24 weeks of follow-up, the mean standardized WOMAC pain subscore improved from 4.3 to 1.3 in the biomechanical footwear group and from 4.0 to 2.6 in the control footwear group (between-group difference in scores at 24 weeks of follow-up, -1.3 [95% CI, -1.8 to -0.9]; P < .001). The results were consistent for WOMAC physical function subscore (between-group difference, -1.1 [95% CI, -1.5 to -0.7]), WOMAC stiffness subscore (between-group difference, -1.4 [95% CI, -1.9 to -0.9]), and WOMAC global score (between-group difference, -1.2 [95% CI, -1.6 to -0.8]) at 24 weeks of follow-up. Three serious adverse events occurred in the biomechanical footwear group compared with 9 in the control footwear group (2.7% vs 8.3%, respectively); none were related to treatment. CONCLUSIONS AND RELEVANCE: Among participants with knee pain from osteoarthritis, use of biomechanical footwear compared with control footwear resulted in an improvement in pain at 24 weeks of follow-up that was statistically significant but of uncertain clinical importance. Further research would be needed to assess long-term efficacy and safety, as well as replication, before reaching conclusions about the clinical value of this device. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02363712.
引用
- Reichenbach S, Felson DT, Hincapié CA, et al. Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis: The BIOTOK Randomized Clinical Trial. JAMA. 2020. PMID: 32396180. doi:10.1001/jama.2020.3565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。